17 years of research by more than 30,000 people tell you the dangers of eating red meat

Share This Post

The latest shows that a diet without red meat significantly reduces the risk of colon cancer in British women. Researchers at the University of Leeds evaluated whether red meat, poultry, fish or vegetarian diets are associated with colon and rectal cancer risk. When comparing the effects of these diets on the development of cancer in specific subpopulations of the colon, they found that those who frequently ate red meat had a higher percentage of cancers in the distal colon than those without a red meat diet-that is, cancers were found in the distal part of the colon, ie Where to store feces.

The study included 32,147 women from England, Wales and Scotland. They were recruited and surveyed by the World Cancer Research Foundation from 1995 to 1998 and tracked for an average of 17 years. In addition to reporting their dietary habits, a total of 462 cases of colorectal cancer, 335 cases of colon cancer, and 119 cases of distant colon cancer were recorded.

By 2030, it is expected that there will be more than 2.2 million new cases of colorectal cancer worldwide, which is the third most commonly diagnosed cancer among British  women. Previous studies have shown that eating large amounts of red meat and processed meat increases the risk of colorectal cancer. It is estimated that about one-fifth of bowel cancers in the UK are related to eating these meats. This study of more than 30,000 people lasted 17 years, and the results are extremely convincing. How should you prevent colorectal cancer, you should know?

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy